| Literature DB >> 32524200 |
Satoshi Kaito1, Atsushi Wada1, Hiroto Adachi1, Ryosuke Konuma1, Yuya Kishida1, Akihito Nagata1, Tatsuya Konishi1, Yuta Yamada1, Takuma Kumagai1, Kota Yoshifuji1, Junichi Mukae1, Megumi Akiyama1, Kyoko Inamoto1, Takashi Toya1, Aiko Igarashi1, Yuho Najima1, Hideharu Muto1, Takeshi Kobayashi1, Kazuhiko Kakihana1, Kazuteru Ohashi1, Hisashi Sakamaki1, Noriko Doki2.
Abstract
Second allogeneic hematopoietic stem cell transplantation (allo-HSCT) has a low survival outcome and a high non-relapse mortality (NRM) rate which is a major obstacle to this treatment. We hypothesized that the status of malnourishment after first allo-HSCT as represented by the geriatric nutritional risk index (GNRI) could be used as a prognostic factor to determine the outcomes of second allo-HSCT. A total of 108 patients with a median age of 42 (range, 17-69) years, who received second allo-HSCT for disease recurrence after first allo-HSCT from our institution, were included in this study. Low GNRI had a significant impact on NRM at 2 years after second allo-HSCT: 56.9% in patients with GNRI ≤ 92 compared with 27.5% in patients with GNRI > 92 (P = 0.002). In multivariate analysis, GNRI of ≤ 92 was the only significant factor for NRM (hazard ratio [HR] 2.29, 95% confidence interval [CI] 1.15-4.56, P = 0.018). High-risk disease status at second allo-HSCT (HR 2.74, 95% CI 1.46-5.14, P = 0.002) and GNRI of ≤ 92 (HR 1.70, 95% CI 1.02-2.82, P = 0.042) were identified as significant factors for overall survival (OS). A score of 1 was assigned to each factor, and the OS rate at 2 years after second allo-HSCT decreased according to the score: 53.0% in patients with score 0, 32.3% with score 1, and 2.5% with score 2 (P < 0.001). In conclusion, GNRI could be a useful predictor for the outcomes of second allo-HSCT. A prospective study in other cohorts is warranted to validate the findings of our study.Entities:
Keywords: Geriatric nutritional risk index; Malnutrition; Second allogeneic hematopoietic stem cell transplantation
Year: 2020 PMID: 32524200 DOI: 10.1007/s00277-020-04089-0
Source DB: PubMed Journal: Ann Hematol ISSN: 0939-5555 Impact factor: 3.673